Teriflunomide for multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  He, Dian ^a   Zhang, Chao ^b   Zhao, Xia ^b   Zhang, Yifan ^a   Dai, Qingqing ^a   Li, Yuan ^a   Chu, Lan ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b Sixth People's Hospital of Jinan   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; TOLUIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; BACKACHE; BIBLIOGRAPHIC DATABASE; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISABILITY; DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAIR DISEASE; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; INFLUENZA; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PYRIMIDINE SYNTHESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADULT; CROTONATES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOLUIDINES; YOUNG ADULT;

EID: 84961927169     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009882.pub3     Document Type: Review

References (83)

1. Comi G, Freedman MS, Kappos L, Miller A, Olsson TP, Wolinsky JS, et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences 2013;333:e376.
2. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology 2014;13(3):247-56.
3. Kappos L, Comi G, Confavreux C, Freedman MS, Miller AE, Olsson TP, et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase , placebo-controlled study. Multiple Sclerosis 2012;18:50-1.
4. Miller A, Kappos L, Comi G, Confavreux C, Freedman M, Olsson T, et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo-controlled study. Neurology. 2013; Vol. 80.
5. Miller AE, Macdonell R, Comi G, Freedman MS, Kappos L, Maurer M, et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology 2014;261(9):1781-8.
6. Moses H, Freedman M, Kappos L, Miller A, Olsson T, Wolinsky J, et al. Pre-defined subgroups analyses of tower, a placebo-controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16-23; San Diego (CA).
7. O'Connor P, Lublin F, Wolinsky J, Comi G, Confavreux C, Freedman M, et al. Teriflunomide reduces relapse-related sequelae, hospitalizations and corticosteroid use: a post-HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16-23; San Diego (CA).
8. Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, et al. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase trial. Neurology 2012;78(23):1877-85.
9. NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon-beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016).
10. Comi G, Benzerdjeb H, Wang L, Truffinet P, O'Connor P. Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science 2013;333(Suppl 1):e376.
11. Comi G, O'Connor P, Wolinsky J, Confavreux C, Kappos L, Olsson T, et al. Extension of a phase trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow-Up. Multiple Sclerosis 2011;17:S182-3.
12. Freedman M, Wolinsky J, Comi G, Kappos L, Olsson T, Miller A, et al. Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis 2013;19:225.
13. Freedman M, Wolinsky J, Comi G, Kappos L, Olsson T, Miller A, et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology 2014; Vol. 82, issue Suppl 10:3-150.
14. Freedman MS, Delhay JL, Benamor M. Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis 2012;18:S13.
15. Miller A, Lublin F, O'Connor P, Taniou C, Dive-Pouletty C. Impact of relapses with sequelae on disability, health-related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase teriflunomide trial. Neurology 2012;78:P07.082.
16. Miller A, Lublin F, O'Connor P, Wolinsky J, Comi G, Kappos L, et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology 2012;78:S30.003.
17. Miller A, O'Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase trial (TEMSO). Multiple Sclerosis 2011;17:S182.
18. Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, et al. Pre-specified subgroup analyses of a placebo-controlled phase trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis 2012;18(11):1625-32.
19. O'Connor P, Briggs A, Carita P, Bego-Le-Bagousse G. Impact on health-related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology 2012;259:S107.
20. O'Connor P, Burrell A, Wang L, Wei L, Carita P, Zhang Q. Effect of teriflunomide on longitudinal patterns of relapse and relapse-related hospitalization in multiple sclerosis. Multiple Sclerosis 2011;17:S414.
21. O'Connor P, Lublin F, Wolinsky J, Comi G, Kappos L, Freedman M, et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis 2011;17:S95-6.
22. O'Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, Olsson T, et al. Extension of a phase trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis 2011;17:S414-5.
23. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine 2011;365(14):1293-303.
24. O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of Neurology 2013;260(10):2472-80.
25. Wolinksy JS, Wang L, Truffinet P, Narayana PA, Nelson F, O'Connor P. Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis 2012;18:470-1.
26. Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, et al. Magnetic resonance imaging outcomes from a phase trial of teriflunomide. Multiple Sclerosis 2013;19(10):1310-9.
27. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. A multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Multiple Sclerosis 2012;18:S9-10.
28. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Journal of Neurology 2012;259:S38.
29. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis 2014;20(6):705-16.
30. Comi G, Miller AE, Wolinsky JS, Benamor M, Bauer D, Truffinet P, et al. The effect of teriflunomide on lymphocyte and neutrophil count in patients with a first clinical episode consistent with multiple sclerosis: results from the TOPIC study. European Journal of Neurology 2014;21:127-8.
31. Miller A, Wolinsky J, Kappos L, Comi G, Freedman M, Olsson T, et al. TOPIC: efficacy and safety of once-daily oral teriflunomide in patients with first clinical episode consistent with multiple sclerosis. Neurology. 2014; Vol. 82.
32. Miller A, Wolinsky J, Kappos L, Comi G, Freedman MS, Olsson T, et al. TOPIC main outcomes: efficacy and safety of once-daily oral teriflunomide in patients with clinically isolated syndrome. Multiple Sclerosis 2013;19:25-6.
33. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology 2014;13(10):977-86.
34. Turner B, Bauer D, Benamor M, Truffinet P, Miller A. Teriflunomide in early stage MS: results from TOPIC. Journal of Neurology, Neurosurgery and Psychiatry 2014;85:A40.
35. Wolinsky JS, Comi G, Kappos L, Bauer D, Truffinet P, Miller AE. Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study. European Journal of Neurology 2014;21:103.
36. Wolinsky JS, Truffinet P, Bauer D, Miller AE. Efficacy of teriflunomide in patients with early stage MS: analysis of the TOPIC study using 2010 McDonald diagnostic criteria. Multiple Sclerosis 2014;20:109-10.
37. Wolinsky JS, Truffinet P, Bauer D, Miller AE. MRI outcomes in patients with early multiple sclerosis treated with teriflunomide: subgroup analyses from the TOPIC phase 3 study. Multiple Sclerosis 2014;20:84.
38. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis 2012;18(9):1278-89.
39. Confavreux C, O'Connor P, Freedman M, Benzerdjeb H, Wang D, Bar-Or A. Long term safety and tolerability of teriflunomide in multiple sclerosis: 9-year follow-up of a phase study. Multiple Sclerosis 2011;17:S409-10.
40. Jumah MA, Li DB, Yamout B, Truffinet P, Dukovic D, O'Connor PW. Long-term clinical and magnetic resonance imaging outcomes from patients treated with teriflunomide: results from a phase 2 extension study. Multiple Sclerosis and Related Disorders 2014;3:755-56.
41. Li D, O'Connor P, Confavreux C, Truffinet P, Wang D, Traboulsee A. Efficacy of teriflunomide in relapsing multiple sclerosis: phase extension study with 8-year follow-up. Multiple Sclerosis 2011;17:S183-4.
42. Li DBK, Traboulsee AL, Truffinet P, Dukovic D, O'Connor PW. Long-term MRI outcomes from patients treated with teriflunomide: results from a phase 2 extension study. Multiple Sclerosis 2014;20:102-3.
43. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, et al. A Phase study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66(6):894-900.
44. Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochemical Journal 1998;336(Pt 2):299-303.
45. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47(1):129-39.
46. Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. Journal of Pharmacology and Experimental Therapeutics 1995;272(1):460-8.
47. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129(Pt 3):606-16.
48. Deage V, Burger D, Dayer JM. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. European Cytokine Network 1998;9(4):663-8.
49. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
50. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999;5(4):251-9.
51. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochemical Pharmacology 1995;50(6):861-7.
52. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41(1):55-68.
53. Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, et al. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Journal of Clinical Pharmacy and Therapeutics 2013;38(6):433-9.
54. Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. British Journal of Pharmacology 1999;127(7):1589-96.
55. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
56. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(1):11-25.
57. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. Journal of Leukocyte Biology 2004;76:950-60.
58. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
59. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
60. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83(3):278-86.
61. Lublin FD. New multiple sclerosis phenotypic classification. European Neurology 2014;72 Suppl:1-5.
62. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. Journal of Immunology 1999;162(4):2095-102.
63. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
64. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50(1):121-7.
65. Merrill JE, Hanak S, Pu SF, Liang J, Dang C, Iglesias-Bregna D, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Journal of Neurology 2009;256(1):89-103.
66. O'Connell K, Kelly SB, Fogarty E, Duggan M, Buckley L, Hutchinson M, et al. Economic costs associated with an MS relapse. Multiple Sclerosis and Related Disorders 2014;3(6):678-83.
67. Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse: the patients perspective. Patient 2012;5(1):57-69.
68. Parisé H, Laliberté F, Lefebvre P, Duh MS, Kim E, Agashivala N, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. Journal of the Neurological Sciences 2013;330(1-2):71-7.
69. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 2005;58(6):840-6.
70. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011;69(2):292-302.
71. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-31.
72. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2015.
73. Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. Journal of Immunology 1998;160(4):1581-8.
74. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. International MS Journal 2008;15(2):62-8.
75. Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD011381]
76. Tullman MJ, Oshinsky RJ, Lublin FD, Cutter GR. Clinical characteristics of progressive relapsing multiple sclerosis. Multiple Sclerosis 2004;10(4):451-4.
77. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of Life Research 1995;4(3):187-206.
78. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
79. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. Journal of Biological Chemistry 1995;270(21):12398-403.
80. Xu X, Williams JW, Gong H, Finnegan A, Chong AS. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochemical Pharmacology 1996;52(4):527-34.
81. Zagmutt FJ, Carroll CA. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. International Journal of Neuroscience 2015;125(11):798-807.
82. Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Hörl WH, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis and Rheumatism 2005;52(9):2730-9.
83. He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD009882.pub2]